A new paradigm of syndromic testing for meningitis and encephalitis

Podcast

Dr. Jaime Fergie, infectious disease expert and epidemiologist at Driscoll Children’s Hospital of Corpus Christi, Texas, looks at syndromic panels that identify bacterial and viral pathogens as a tool to guide pediatricians in the management and treatment of infections in their young patients, and specifically at a new panel for meningitis and encephalitis that can revolutionize diagnosis of these diseases.

Additional Resources:

Association of the FilmArray Meningitis/Encephalitis Panel With Clinical Management

By: Aleisha M Nabower

Learn More

Impact of Cerebrospinal Fluid Multiplex Assay on Diagnosis and Outcomes of Central Nervous System Infections in Children: A Before and After Cohort Study

By: Matthew P O'Brien

Learn More

One Year in the Life of a Rapid Syndromic Panel for Meningitis/Encephalitis: A Pediatric Tertiary Care Facility's Experience

By: Samia N Naccache

Learn More

Recent Videos
cUTI Roundtable: Discussing and diagnosing these difficult infections
Willough Jenkins, MD
Discussing health care sustainability, climate change, and WHO's One Health goal | Image credit: Provided by Shreya Doshi
Willough Jenkins, MD
Screening for and treating the metatarsus adductus foot deformity | Image Credit: UNFO md ltd
Wendy Ripple, MD
Wendy Ripple, MD
Courtney Nelson, MD
DB-OTO improved hearing to normal in child with profound genetic deafness | Image Credit: © Marija - © Marija - stock.adobe.com.
Related Content
FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome | Image Credit: © wladimir1804 - © wladimir1804 - stock.adobe.com.

FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome

Celeste Krewson, Assistant Editor
July 25th 2024
Article

ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA expands maralixibat label to include PFIC patients aged 12 months and older | Image Credit: © Calin - © Calin - stock.adobe.com.

FDA expands maralixibat label to include PFIC patients aged 12 months and older

Joshua Fitch, Senior Editor
July 25th 2024
Article

Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
cUTI Roundtable: The Latest Therapeutic Developments

cUTI Roundtable: The Latest Therapeutic Developments

Joshua Fitch, Senior Editor ;John Parkinson;Morgan Petronelli, Managing Editor
July 24th 2024
Article

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results | Image Credit: © Guru - © Guru - stock.adobe.com.

Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results

Joshua Fitch, Senior Editor
July 24th 2024
Article

Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.

© 2024 MJH Life Sciences

All rights reserved.